Price List - Tezruly - BPH - Selective Alpha-1 Antagonists.xlsx
XLSX spreadsheet 47 KB Posted
- Solicitation number
- HT9402-25-Q-9302
- Issued by
-
Defense Health Agency
About this file
This is a Price List Excel file for the Department of Defense (DoD) Pharmacy Uniform Formulary Blanket Purchase Agreement (BPA) for Benign Prostatic Hyperplasia (BPH) Agents, specifically Selective Alpha-1 Antagonists, targeting the August 2025 P&T Committee Meeting. The document outlines pricing and formulary scenarios for up to 10 newly approved drugs, with quotes due on May 15, 2025, and a P&T Committee meeting scheduled for August 6-7, 2025.
The file includes detailed pricing appendices for both Blanket Purchase Agreement and Additional Discount Program, with multiple formulary scenarios for Uniform Formulary, Non-Formulary, Tier 2, and Tier 3 categories. Key notes indicate that prior authorization may apply, and the P&T Committee reserves the right to recommend preferential status, cost-sharing adjustments, or potential exclusion from the TRICARE pharmacy benefit program. Manufacturers are instructed to submit fully executed signature pages with quote information, and pricing calculations involve complex formulas including non-FAMP (Federal Acquisition Medicaid Price), WAC (Wholesale Acquisition Cost), and various discount percentages.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Price List - Qfitlia - Antihemophilic Agents - Non-Factor Agents.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price Appendix FAQ NAD.pdf | ||
| RFQ HT9402-25-Q-9302 NAD.pdf | ||
| Price List - Combogesic - Analgesics and Combination - NA.xlsx | XLSX spreadsheet | |
| Price List - Vanrafia - Nephrology Agents Miscellaneous - NA.xlsx | XLSX spreadsheet |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the August 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 |
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 254BPSAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 254BPSAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 254BPSAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 254BPSAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 254BPSAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 254BPSAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 254BPSAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 254BPSAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 254BPSAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 254BPSAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 254BPSAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 254BPSAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 254BPSAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 254BPSAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 254BPSAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 254BPSAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 254BPSAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 254BPSAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 254BPSAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 254BPSAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the August 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 |
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (WAC Discount)
| UF ADP Appendix for the August 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 |
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | BENIGN PROSTATIC HYPERPLASIA AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | SELECTIVE ALPHA-1 ANTAGONISTS | Quotes due: | May 15, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 254BPSAG1T21M | Tier 2 | 1 or more | |
| 254BPSAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .